Joe Liebeschuetz, partner in the firm’s Intellectual Property Group, was quoted in a Law360 article discussing the significance of the Supreme Court’s ruling that human genes cannot be patented, striking down Myriad Genetics, Inc.’s, patents on isolated DNA associated with an increased risk of breast cancer.
“Despite the invalidation of analogous claims in [3,000] patents implied by the decision, the positive reaction of the stock market shows relief that the decision did not go even further in reshaping the contours of patentable subject matter,” Liebeschuetz said.
“Isolated DNA now lies outside the bounds of patentable subject matter in the United States, but cDNA and presumably other manipulated forms of DNA or other biomolecules can still be patented by appropriately drafted claims going forward,” he explained.
Additionally, Mr. Liebeschuetz wrote an article titled "How Myriad's Once Unthinkable Result Became Expected," which was featured in The Daily Journal.